Synthego and ATCC Enter Alliance for Cutting-Edge Gene Editing of Mammalian and Mouse Cell Lines

REDWOOD CITY, CA, June 28, 2023 - Synthego, a leading genome engineering company, is pleased to announce a groundbreaking partnership with ATCC, the premier non-profit global biological materials and standards resource center, to provide researchers with an extensive collection of mammalian and mouse cell lines for gene editing applications, including Express Cell Pools to increase speed to results.

This alliance brings together Synthego's expertise in genome engineering and ATCC's renowned reputation as a trusted provider of authenticated biological materials and standards. CRISPR-edited cell pools are indispensable tools for many research applications, from disease modeling to loss-of-function screens and drug discovery. By leveraging Synthego's innovative CRISPR solutions and ATCC's vast cell line collection, researchers will gain unparalleled access to a comprehensive range of cell models and invaluable scientific resources, accelerating research breakthroughs and advancing the field of genetic engineering.

Synthego's Gene Engineering Platform, powered by advanced CRISPR technology, enables precise and efficient gene editing, enabling scientists to unlock the full potential of their research. The collaboration will facilitate the expedited delivery of genome edited cell lines specifically tailored for drug discovery applications. Additionally, this will ensure that researchers can have timely access to a diverse array of fully characterized and validated mammalian and mouse cell lines, meeting the highest standards of quality and reproducibility.

"We are thrilled to join forces with ATCC to provide researchers with cutting-edge CRISPR tools and resources for obtaining edited cell pools that can be used directly in many assays," said Paul Dabrowski, CEO of Synthego. "Researchers now have the option to skip labor-intensive genome engineering in their lab, in many cases also avoid months of waiting for clones, and instead leverage Synthego Engineering of ATCC cells."

"Together with Synthego, we're enabling disease modeling at scale, and enabling discovery and validation with ease and speed," said Raymond H. Cypess, D.V.M., Ph.D., chairman and CEO of ATCC. "We are committed to continuing to be a foundational player in the biotechnology industry as our biomaterials are critical to expanding global research and development pipelines."

Both ATCC and Synthego are committed to fostering innovation and collaboration in the life sciences industry. The combined expertise of Synthego and ATCC will empower scientists, accelerate scientific breakthroughs, and contribute to the development of novel therapeutics, diagnostic tools, and precision medicine solutions.

For more information about Synthego's innovative Cell Line Engineering and gene editing solutions, please visit www.synthego.com. To explore ATCC's extensive collection of cell lines and biological materials, please visit www.atcc.org.